ClinicalTrials.gg
TerminatedNCT02984618Updated Feb 28, 2020

Sphenopalatine Block or Epidural Bloodpatch for Post Dural Puncture Headache: Randomized Controlled Trial

An interventional study of Sphenopalatine ganglion block and Epidural blood patch in Post-Dural Puncture Headache, sponsored by Brasilia University Hospital. Terminated at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-28.

Sponsored by Brasilia University Hospital · Not applicable, Interventional, and Treatment

Why this study was terminated
High recurrence of headache in SPG group.
Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Introduction: Recently sphenopalatine block emerged as an alternative to epidural blood patch for post dural puncture headache but the investigators do not know if it has significant efficacy when compared to epidural blood patch. Method: randomized trial where patients will randomly receive either sphenopalatine block or epidural blood patch. Pain relief to no pain or low intensity pain will be the main outcome

Read the detailed description

Introduction: Recently sphenopalatine block emerged as an alternative to epidural blood patch for post dural puncture headache but the investigators do not know if it has significant efficacy when compared to epidural blood patch. Method: randomized clinical trial where patients with moderate to severe post dural puncture pain will randomly receive either sphenopalatine block or epidural blood patch. Pain relief to no pain or low intensity pain will be the main outcome. Pain recurrence, survival without pain and side effects (tinitus, low back pain, new dural puncture, sore throat) will be secondary outcomes.

02

Conditions studied

  • Post-Dural Puncture Headache
03

In context

Post-Dural Puncture Headache

122 studies on the registry are indexed under Post-Dural Puncture Headache; 27 are open to participants now.

This study's enrollment of 19 is below the median of 80 across 79 interventional studies indexed under Post-Dural Puncture Headache.

Browse Post-Dural Puncture Headache studies →

Lead sponsor

Brasilia University Hospital is the lead sponsor of 20 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnostic criteria for post dural puncture headache
  • Moderate to severe post dural puncture headache

Exclusion criteria

Exclusion Criteria:

  • Procedure failures: new dural puncture on epidural blood patch trial, unable to find epidural space, intolerance to insertion of nasal swabs.
  • Follow up loss
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Treatment group

    Patients will receive sphenopalatine ganglion block with ropivacaine 0.375% 3ml on each side

    Procedure: Sphenopalatine ganglion block

  • Active comparator
    Control group

    Patients will receive classic epidural blood patch with 20ml of autologous blood

    Procedure: Epidural blood patch

Interventions

  • ProcedureSphenopalatine ganglion block

    Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.

  • ProcedureEpidural blood patch

    Autologous sterile blood (20ml) will be infused in the lombar epidural space.

06

What researchers measure

Primary outcomes

  1. Pain relief

    Pain assessed by categorical verbal scale (no pain, low pain, moderate pain or severe pain) 30 minutes after the procedure.

    Time frame: Pain reduction to no pain or low pain within 30 minutes of the intervention.

Secondary outcomes

  1. Tinitus

    Time frame: Incidence (dichotomic) of tinutus within 24 hours after the procedure.

  2. Low back pain

    Time frame: Incidence (dichotomic) of low back pain within 24 hours after the procedure.

  3. Sore throat

    Time frame: Incidence (dichotomic) of sore throat within 24 hours after the procedure.

Other outcomes

  1. Pain relief survival

    Patients will be contacted for the first two weeks for monitoring new headache onsets.

    Time frame: Incidence of new headache onset during the first two weeks

07

Study locations

1 site
  • Hospital Universitário de Brasilia
    Brasilia, Distrito Federal 70000000, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Dec 2019, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2016
First posted
Dec 7, 2016
StartActual
Dec 1, 2016
Primary completionActual
Dec 20, 2019
CompletionActual
Dec 20, 2019
Last update
Feb 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02984618
Lead sponsor
Brasilia University Hospital
Responsible party
Gabriel Magalhaes Nunes Guimaraes (Substitute professor of Anesthesiology, Brasilia University Hospital) — Principal investigator
First posted
Dec 7, 2016
Start date
Dec 1, 2016
Primary completion
Dec 20, 2019
Completion
Dec 20, 2019
Last update
Feb 28, 2020

Study contacts

Gabriel MN Guimaraes, MsC, MD
principal investigator · Universidade de Brasilia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion